These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 24355485)

  • 21. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
    Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS
    Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
    Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
    Michelsen TM; Dørum A; Dahl AA
    Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reproductive issues for women with BRCA mutations.
    Friedman LC; Kramer RM
    J Natl Cancer Inst Monogr; 2005; (34):83-6. PubMed ID: 15784831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
    Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study.
    Brandberg Y; Arver B; Johansson H; Wickman M; Sandelin K; Liljegren A
    Eur J Surg Oncol; 2012 Jan; 38(1):38-43. PubMed ID: 22032910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A
    Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
    J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
    Phillips KA; Jenkins MA; Lindeman GJ; McLachlan SA; McKinley JM; Weideman PC; Hopper JL; Friedlander ML;
    Clin Genet; 2006 Sep; 70(3):198-206. PubMed ID: 16922722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidisciplinary one-stage risk-reducing gynaecological and breast surgery with immediate reconstruction in BRCA-gene carrier women.
    Khadim MF; Eastwood P; Price J; Morrison P; Khan K
    Eur J Surg Oncol; 2013 Dec; 39(12):1346-50. PubMed ID: 24113619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
    Salyer C; Kobelka C; Barrie A; Weintraub MR; Powell CB
    Gynecol Oncol; 2019 Aug; 154(2):374-378. PubMed ID: 31160070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.
    Mannis GN; Fehniger JE; Creasman JS; Jacoby VL; Beattie MS
    JAMA Intern Med; 2013 Jan; 173(2):96-103. PubMed ID: 23247828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives in the clinical management of BRCA mutations carriers.
    Savarese A; Cognetti F
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA mutation genetic testing implications in the United States.
    Bayraktar S; Arun B
    Breast; 2017 Feb; 31():224-232. PubMed ID: 27931006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.